Serbian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
11 резултати
Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
TECHNICAL FIELD
The present invention relates to a nitrogen-containing bicyclic compound or a pharmacologically acceptable salt thereof and a pharmaceutical composition comprising it as active ingredient.
More specifically, the present invention relates to (1) a compound of formula (I)
##STR00002##
Substituted benzopyrans as selective estrogen receptor-beta agonists
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND OF THE INVENTION
The present invention relates to novel benzopyran ER-.beta. agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-.beta. mediated disease such as benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon
Piperidine derivative compounds and drugs containing the compounds as the active ingredient
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
TECHNICAL FIELD
The present invention relates to a piperidine derivative.
More specifically, the present invention relates to (1) a piperidine derivative of formula (I)
##STR00002## (2) a method for the preparation thereof, (3) a composition comprising it as an active ingredient, (4) a compound of
LKB1-AMPK activators for therapeutic use in polycystic kidney disease
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND
Autosomal dominant polycystic kidney disease (ADPKD) is a frequently inherited kidney disorder with a gene frequency of 1 in 500 to 1,000 births affecting nearly 600,000 Americans and as many as 12 million people worldwide. This potentially lethal genetic disease is characterized by the
LKB1-AMPK activators for therapeutic use in polycystic kidney disease
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND
Autosomal dominant polycystic kidney disease (ADPKD) is a frequently inherited kidney disorder with a gene frequency of 1 in 500 to 1,000 births affecting nearly 600,000 Americans and as many as 12 million people worldwide. This potentially lethal genetic disease is characterized by the
Methods of screening for compounds which bind G protein-coupled receptors
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the 35 U.S.C. .sctn.371 national stage of PCT application PCT/JP2005/007354, filed Apr. 11, 2005, which claims priority to Japanese patent application No. 116725/2004, filed Apr. 12, 2004. The contents of these applications are incorporated
Compounds for binding to ER alpha/beta and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
FIELD OF THE INVENTION
The present invention relates to compounds which modulate one or more of ERalpha/beta and GPR30 receptors, to pharmaceutical compositions based upon those compounds and to methods of treating disease states and conditions mediated through these receptors and related methods
Compounds for binding to ER.alpha./.beta. and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
FIELD OF THE INVENTION
The present invention relates to compounds which modulate one or more of ERalpha/beta and GPR30 receptors, to pharmaceutical compositions based upon those compounds and to methods of treating disease states and conditions mediated through these receptors and related methods
Substituted tetralins as selective estrogen receptor-.beta. agonists
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND OF THE INVENTION
The present invention relates to novel tetralin ER-.beta. agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-.beta. mediated disease such as benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon
Piperidine derivatives and agent comprising the derivative as active ingredient
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
TECHNICAL FIELD
The present invention relates to piperidine derivatives.
More specifically, the present invention relates to
(1) piperidine derivatives represented by formula (I):
##STR00002## (wherein all symbols have the same meanings as described below), or nontoxic salts thereof, (2) a process
Piperidine derivatives and agent comprising the derivative as active ingredient
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
TECHNICAL FIELD
The present invention relates to piperidine derivatives.
More specifically, the present invention relates to (1) piperidine derivatives represented by formula (I):
##STR00002## (wherein all symbols have the same meanings as described below), or nontoxic salts thereof, (2) a process
Најкомплетнија база лековитог биља подржана науком
- Ради на 55 језика
- Биљни лекови потпомогнути науком
- Препознавање биљака по слици
- Интерактивна ГПС мапа - означите биље на локацији (ускоро)
- Читајте научне публикације повезане са вашом претрагом
- Претражите лековито биље по њиховим ефектима
- Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима
Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима
